DPP4 deficiency preserved cardiac function in abdominal aortic banding rats

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Ku, Hui Chun ^a   Su, Ming Jai ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; COLLAGEN; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1;

ABDOMINAL AORTIC BANDING; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA SURGERY; ARTICLE; BIOACCUMULATION; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HISTOLOGY; MALE; NONHUMAN; RAT; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; CARDIOMEGALY; COLLAGEN; DIPEPTIDYL PEPTIDASE 4; GLUCAGON-LIKE PEPTIDE 1; HEART FUNCTION TESTS; HEMODYNAMICS; MALE; PRESSURE; RATS; RATS, INBRED F344; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84897899114     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085634     Document Type: Article

References (56)

1. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 128: 191-227.
2. Stefan N, Fritsche A, Haring HU (2005) Insulin resistance and congestive heart failure. Jama 294: 2578; author reply 2578.
3. Boudina S, Abel ED (2010) Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11: 31-39.
4. Carley AN, Severson DL (2005) Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734: 112-126. (Pubitemid 40724778)
5. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, et al. (2009) Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54: 1524-1532.
6. Fehmann HC, Goke R, Goke B (1995) Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocr Rev 16: 390-410.
7. Morimoto C, Schlossman SF (1998) The structure and function of CD26 in the T-cell immune response. Immunol Rev 161: 55-70.
8. Doupis J, Veves A (2008) DPP4 inhibitors: a new approach in diabetes treatment. Adv Ther 25: 627-643.
9. Michel MC, Fliers E, Van Noorden CJ (2008) Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? Naunyn Schmiedebergs Arch Pharmacol 377: 205-207.
10. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, et al. (2013) Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy-focus on alogliptin. Drug Des Devel Ther 7: 989-1001.
11. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, et al. (2008) Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350. (Pubitemid 351653542)
12. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, et al. (2003) Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144: 2242-2252. (Pubitemid 36629873)
13. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, et al. (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58: 975-983.
14. Ku HC, Chen WP, Su MJ (2010) GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 382: 463-474.
15. Ku HC, Chen WP, Su MJ (2011) DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 384: 197-207.
16. Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, et al. (2011) Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 6: e17178.
17. Monji A, Mitsui T, Bando YK, Aoyama M, Shigeta T, et al. (2013) Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes. Am J Physiol Heart Circ Physiol 305: H295-304.
18. Liu J, Liu Y, Chen L, Wang Y, Li J (2013) Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress Pathway. J Diabetes Res 2013: 630537.
19. Wang XM, Yang YJ, Wu YJ (2013) The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives. Cardiovasc Drugs Ther 27: 297-307.
20. Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, et al. (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59: 1063-1073.
21. Ku HC, Chen WP, Su MJ (2013) DPP4 deficiency exerts protective effect against H2O2 induced oxidative stress in isolated cardiomyocytes. PLoS One 8: e54518.
22. Scheen AJ (2013) Cardiovascular effects of gliptins. Nat Rev Cardiol 10: 73-84.
23. Monami M, Ahren B, Dicembrini I, Mannucci E (2013) Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15: 112-120.
24. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, et al. (2013) Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. N Engl J Med.
25. Patten RD, Hall-Porter MR (2009) Small animal models of heart failure: development of novel therapies, past and present. Circ Heart Fail 2: 138-144.
26. Ni L, Zhou C, Duan Q, Lv J, Fu X, et al. (2011) beta-AR blockers suppresses ER stress in cardiac hypertrophy and heart failure. PLoS One 6: e27294.
27. Chen WP, Tzeng HJ, Ku HC, Ho YJ, Lee SS, et al. (2010) Thaliporphine ameliorates cardiac depression in endotoxemic rats through attenuating TLR4 signaling in the downstream of TAK-1 phosphorylation and NF-kappaB signaling. Naunyn Schmiedebergs Arch Pharmacol 382: 441-453.
28. Klemann C, Schade J, Pabst R, Leitner S, Stiller J, et al. (2009) CD26/dipeptidyl peptidase 4-deficiency alters thymic emigration patterns and leukcocyte subsets in F344-rats age-dependently. Clin Exp Immunol 155: 357-365.
29. Guinto PJ, Haim TE, Dowell-Martino CC, Sibinga N, Tardiff JC (2009) Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol 297: H614-626.
30. Hasenfuss G (1998) Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37: 279-289.
31. Ashrafian H, McKenna WJ, Watkins H (2011) Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy. Circ Res 109: 86-96.
32. East JM (2000) Sarco(endo)plasmic reticulum calcium pumps: recent advances in our understanding of structure/function and biology (review). Mol Membr Biol 17: 189-200.
33. Monte del F, Harding SE, Dec GW, Gwathmey JK, Hajjar RJ (2002) Targeting phospholamban by gene transfer in human heart failure. Circulation 105: 904-907.
34. Dos Santos L, Salles TA, Arruda-Junior DF, Campos LC, Pereira AC, et al. (2013) Circulating Dipeptidyl Peptidase IV Activity Correlates with Cardiac Dysfunction in Human and Experimental Heart Failure. Circ Heart Fail.
35. Takahashi A, Asakura M, Ito S, Min KD, Shindo K, et al. (2013) Dipeptidylpeptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice. Am J Physiol Heart Circ Physiol 304: H1361-1369.
36. Neubauer S (2007) The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151.
37. van Bilsen M, van Nieuwenhoven FA, van der Vusse GJ (2009) Metabolic remodelling of the failing heart: beneficial or detrimental? Cardiovasc Res 81: 420-428.
38. Liao R, Jain M, Cui L, D'Agostino J, Aiello F, et al. (2002) Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106: 2125-2131. (Pubitemid 35192820)
39. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, et al. (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961. (Pubitemid 39128621)
40. Khan MA, Deaton C, Rutter MK, Neyses L, Mamas MA (2013) Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. Heart Fail Rev 18: 141-148.
41. Zhao TC (2013) Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protection. Cardiovasc Diabetol 12: 90.
42. Nikolaidis LA, Elahi D, Shen YT, Shannon RP (2005) Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-2408. (Pubitemid 41698549)
43. Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, et al. (2010) Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 9: 76.
44. Fisman EZ, Tenenbaum A (2009) A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 8: 38.
45. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, et al. (2013) A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127: 74-85.
46. Lee SA, Kim YR, Yang EJ, Kwon EJ, Kim SH, et al. (2011) CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 98: 2553-2561.
47. Kappe C, Tracy LM, Patrone C, Iverfeldt K, Sjoholm A (2012) GLP-1 secretion by microglial cells and decreased CNS expression in obesity. J Neuroinflammation 9: 276.
48. Sabbah HN (2000) Apoptotic cell death in heart failure. Cardiovasc Res 45: 704-712.
49. Biernacka A, Frangogiannis NG (2011) Aging and Cardiac Fibrosis. Aging Dis 2: 158-173.
50. Brilla CG (2000) Renin-angiotensin-aldosterone system and myocardial fibrosis. Cardiovasc Res 47: 1-3.
51. Bouzegrhane F, Thibault G (2002) Is angiotensin II a proliferative factor of cardiac fibroblasts? Cardiovasc Res 53: 304-312. (Pubitemid 34117680)
52. Skov J, Dejgaard A, Frokiaer J, Holst JJ, Jonassen T, et al. (2013) Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. J Clin Endocrinol Metab 98: E664-671.
53. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, et al. (2009) Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 380: 44-49.
54. Chaykovska L, von Websky K, Rahnenfuhrer J, Alter M, Heiden S, et al. (2011) Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 6: e27861.
55. Zaruba MM, Theiss HD, Vallaster M, Mehl U, Brunner S, et al. (2009) Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell 4: 313-323.
56. Thompson MA, Ohnuma K, Abe M, Morimoto C, Dang NH (2007) CD26/dipeptidyl peptidase IV as a novel therapeutic target for cancer and immune disorders. Mini Rev Med Chem 7: 253-273. (Pubitemid 46488249)